PDC*line Pharma obtains authorization to launch phase I/II trial of its cancer vaccine (PDC*lung01) in non- small cell lung cancer
Liège, Belgium, and Grenoble, France, May 7, 2019 - PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today that the Belgian Federal Agency for Medicines Health Product (FAMHP), together with the designated Ethics Committee, have authorized the initiation of an open-label, dose-escalation, phase I/II trial with its cancer vaccine candidate (PDC*lung01) for non-small-cell lung cancer (NSCLC).
